Dynavax Technologies beats Q2 revenue expectations

Dynavax Technologies

07/08/2025 21:07

Overview

Dynavax Q2 revenue rises 29%, beating analyst expectations, per LSEG data

HEPLISAV-B achieves record net product revenue of $92 mln, up 31% yr/yr

Co refines full-year HEPLISAV-B revenue guidance to $315-$325 mln

Outlook

Dynavax raises 2025 HEPLISAV-B revenue guidance to $315-$325 mln

Company expects U.S. hepatitis B vaccine market to exceed $900 mln by 2030

HEPLISAV-B to achieve at least 60% U.S. market share by 2030

Company anticipates reporting shingles vaccine trial results in August 2025

Result Drivers

HEPLISAV-B SALES - Record quarterly net product revenue of $91.9 mln, driven by increased market share in U.S. adult hepatitis B vaccine market

MARKET SHARE GAIN - HEPLISAV-B U.S. market share increased to approximately 45%, up from 42% year-ago

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$95.44 mln
$86.70 mln (4 Analysts)
Q2 EPS
$0.16
Q2 Net Income
$18.72 mln
Q2 Operating Expenses
$81.01 mln
Q2 Operating Income
$14.43 mln
Q2 Pretax Profit
$21.22 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Dynavax Technologies Corp is $25.00, about 55.2% above its August 6 closing price of $11.19

The stock recently traded at 87 times the next 12-month earnings vs. a P/E of 27 three months ago

Press Release: ID:nPn9RbSfba

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)